vs
AvalonBay Communities（AVB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是AvalonBay Communities的1.0倍（$772.1M vs $767.9M），AvalonBay Communities净利率更高（9040.6% vs 12.7%，领先9027.8%），Revvity同比增速更快（5.9% vs 3.7%），AvalonBay Communities自由现金流更多（$1.4B vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 3.8%）
AvalonBay Communities是一家公开上市的房地产投资信托（REIT），核心业务聚焦公寓类不动产的投资与运营，旗下持有并管理大量区位优质的公寓项目，为租户提供高品质居住服务，在北美住宅地产投资领域拥有较高知名度。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AVB vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$767.9M
营收增速更快
RVTY
高出2.2%
3.7%
净利率更高
AVB
高出9027.8%
12.7%
自由现金流更多
AVB
多$1.2B
$161.8M
两年增速更快
RVTY
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $767.9M | $772.1M |
| 净利润 | $166.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 64.2% | 14.5% |
| 净利率 | 9040.6% | 12.7% |
| 营收同比 | 3.7% | 5.9% |
| 净利润同比 | -41.2% | 3.9% |
| 每股收益（稀释后） | $1.18 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVBRVTY
| Q4 25 | $767.9M | $772.1M | ||
| Q3 25 | $766.8M | $698.9M | ||
| Q2 25 | $760.2M | $720.3M | ||
| Q1 25 | $745.9M | $664.8M | ||
| Q4 24 | $740.5M | $729.4M | ||
| Q3 24 | $734.3M | $684.0M | ||
| Q2 24 | $726.0M | $691.7M | ||
| Q1 24 | $712.9M | $649.9M |
净利润AVBRVTY
| Q4 25 | $166.0M | $98.4M | ||
| Q3 25 | $381.3M | $46.7M | ||
| Q2 25 | $268.7M | $53.9M | ||
| Q1 25 | $236.6M | $42.2M | ||
| Q4 24 | $282.1M | $94.6M | ||
| Q3 24 | $372.5M | $94.4M | ||
| Q2 24 | $253.9M | $55.4M | ||
| Q1 24 | $173.4M | $26.0M |
毛利率AVBRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率AVBRVTY
| Q4 25 | 64.2% | 14.5% | ||
| Q3 25 | 65.7% | 11.7% | ||
| Q2 25 | 67.6% | 12.6% | ||
| Q1 25 | 68.5% | 10.9% | ||
| Q4 24 | 63.1% | 16.3% | ||
| Q3 24 | 65.4% | 14.3% | ||
| Q2 24 | 66.6% | 12.4% | ||
| Q1 24 | 67.2% | 6.8% |
净利率AVBRVTY
| Q4 25 | 9040.6% | 12.7% | ||
| Q3 25 | 49.7% | 6.7% | ||
| Q2 25 | 35.3% | 7.5% | ||
| Q1 25 | 31.7% | 6.4% | ||
| Q4 24 | 38.1% | 13.0% | ||
| Q3 24 | 50.7% | 13.8% | ||
| Q2 24 | 35.0% | 8.0% | ||
| Q1 24 | 24.3% | 4.0% |
每股收益（稀释后）AVBRVTY
| Q4 25 | $1.18 | $0.86 | ||
| Q3 25 | $2.68 | $0.40 | ||
| Q2 25 | $1.88 | $0.46 | ||
| Q1 25 | $1.66 | $0.35 | ||
| Q4 24 | $1.99 | $0.77 | ||
| Q3 24 | $2.61 | $0.77 | ||
| Q2 24 | $1.78 | $0.45 | ||
| Q1 24 | $1.22 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $187.2M | $919.9M |
| 总债务越低越好 | $9.3B | — |
| 股东权益账面价值 | $11.6B | $7.3B |
| 总资产 | $22.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资AVBRVTY
| Q4 25 | $187.2M | $919.9M | ||
| Q3 25 | $123.3M | $931.4M | ||
| Q2 25 | $102.8M | $991.8M | ||
| Q1 25 | $53.3M | $1.1B | ||
| Q4 24 | $108.6M | $1.2B | ||
| Q3 24 | $552.4M | $1.2B | ||
| Q2 24 | $545.8M | $2.0B | ||
| Q1 24 | $287.9M | $1.7B |
总债务AVBRVTY
| Q4 25 | $9.3B | — | ||
| Q3 25 | $8.7B | — | ||
| Q2 25 | $8.7B | — | ||
| Q1 25 | $8.3B | — | ||
| Q4 24 | $8.1B | — | ||
| Q3 24 | $8.4B | — | ||
| Q2 24 | $8.4B | — | ||
| Q1 24 | $8.0B | — |
股东权益AVBRVTY
| Q4 25 | $11.6B | $7.3B | ||
| Q3 25 | $11.9B | $7.4B | ||
| Q2 25 | $11.9B | $7.6B | ||
| Q1 25 | $11.9B | $7.6B | ||
| Q4 24 | $11.9B | $7.7B | ||
| Q3 24 | $11.9B | $7.9B | ||
| Q2 24 | $11.7B | $7.9B | ||
| Q1 24 | $11.7B | $7.8B |
总资产AVBRVTY
| Q4 25 | $22.2B | $12.2B | ||
| Q3 25 | $21.9B | $12.1B | ||
| Q2 25 | $21.8B | $12.4B | ||
| Q1 25 | $21.2B | $12.4B | ||
| Q4 24 | $21.0B | $12.4B | ||
| Q3 24 | $21.3B | $12.8B | ||
| Q2 24 | $21.0B | $13.4B | ||
| Q1 24 | $20.6B | $13.4B |
负债/权益比AVBRVTY
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.7B | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $1.4B | $161.8M |
| 自由现金流率自由现金流/营收 | 183.5% | 21.0% |
| 资本支出强度资本支出/营收 | 34.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 10.07× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $2.5B | $509.4M |
8季度趋势，按日历期对齐
经营现金流AVBRVTY
| Q4 25 | $1.7B | $182.0M | ||
| Q3 25 | $477.0M | $138.5M | ||
| Q2 25 | $377.8M | $134.3M | ||
| Q1 25 | $415.9M | $128.2M | ||
| Q4 24 | $1.6B | $174.2M | ||
| Q3 24 | $486.2M | $147.9M | ||
| Q2 24 | $380.0M | $158.6M | ||
| Q1 24 | $412.9M | $147.6M |
自由现金流AVBRVTY
| Q4 25 | $1.4B | $161.8M | ||
| Q3 25 | $402.2M | $120.0M | ||
| Q2 25 | $317.1M | $115.5M | ||
| Q1 25 | $367.5M | $112.2M | ||
| Q4 24 | $1.4B | $149.8M | ||
| Q3 24 | $434.2M | $125.6M | ||
| Q2 24 | $333.0M | $136.6M | ||
| Q1 24 | $375.4M | $129.7M |
自由现金流率AVBRVTY
| Q4 25 | 183.5% | 21.0% | ||
| Q3 25 | 52.5% | 17.2% | ||
| Q2 25 | 41.7% | 16.0% | ||
| Q1 25 | 49.3% | 16.9% | ||
| Q4 24 | 191.0% | 20.5% | ||
| Q3 24 | 59.1% | 18.4% | ||
| Q2 24 | 45.9% | 19.7% | ||
| Q1 24 | 52.7% | 20.0% |
资本支出强度AVBRVTY
| Q4 25 | 34.1% | 2.6% | ||
| Q3 25 | 9.8% | 2.6% | ||
| Q2 25 | 8.0% | 2.6% | ||
| Q1 25 | 6.5% | 2.4% | ||
| Q4 24 | 26.1% | 3.4% | ||
| Q3 24 | 7.1% | 3.3% | ||
| Q2 24 | 6.5% | 3.2% | ||
| Q1 24 | 5.3% | 2.7% |
现金转化率AVBRVTY
| Q4 25 | 10.07× | 1.85× | ||
| Q3 25 | 1.25× | 2.97× | ||
| Q2 25 | 1.41× | 2.49× | ||
| Q1 25 | 1.76× | 3.03× | ||
| Q4 24 | 5.70× | 1.84× | ||
| Q3 24 | 1.31× | 1.57× | ||
| Q2 24 | 1.50× | 2.87× | ||
| Q1 24 | 2.38× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVB
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
